Impact BioMedical to issue 31.9M shares to DSS to settle $12M debt

IMPACT BIOMEDICAL INC.

Issued 31,939,778 shares of common stock to DSS Inc. to fully satisfy $12M revolving promissory note from March 2023.
Original note was amended Jan 2024 to extend maturity to Sept 30, 2023, eliminate advance feature, set repayment terms, adjust interest to WSJ Prime + 0.5%.
Shares are freely tradeable and settle all amounts owed under the note and any additional support between June 21, 2025 and closing.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.